Prognostic features, treatment outcomes and survival of hepatocellular carcinoma patients in National Kidney and Transplant Institute.
- Author:
Rei Joseph PRIETO
;
Jade JAMIAS
- Publication Type:Journal Article, Original
- MeSH: Human; Male; Female; Carcinoma, Hepatocellular; Hepatitis B Virus; Hepatitis B, Chronic; Cytidine Triphosphate; Portal Vein; Liver Neoplasms; Liver Cirrhosis; Kaplan-meier Estimate; Thrombosis
- From: Philippine Journal of Internal Medicine 2016;54(3):1-8
- CountryPhilippines
-
Abstract:
BACKGROND: Hepatocellular carcinoma (HCC) is a primary tumor of the liver, which develops in the setting of chronic liver disease. In the Philippines, despite being the third leading site of cancer, there are limited studies on prognostic factors, treatment outcomes and survival.
Objectives: This study aims to investigate prognostic features, treatment outcomes and survival of HCC patients in our institution.
METHODOLOGY: Retrospective cohort study was employed. All consecutive patients diagnosed with HCC in our institution from January 2008 to December 2014 were included. Demographic data, tumor characteristics, risk factors and treatment outcomes were retrieved through
review of medical records. Cox regression and Kaplan-Meier survival analyses were used to identify prognostic factors and estimate survival, respectively. Statistical analyses were performed with STATA v13.
RESULTS: A total of 346 patients were included. Mean age was 61.47+13.08 years. 55.78% had hepatitis B virus (HBV) infection, 65.15% had cirrhosis solitary nodule (55.08%)
was the dominant tumor pattern, mostly involving the right lobe (51.85%) and >3cm (85.48%) in diameter. 43.5% were barcelona clinic liver cancer (BCLC) stage B and 43.81% had advanced stage on presentation (BCLC C/D). Majority did not have portal vein thrombosis (PVT) and distant metastasis. Overall median survival was 13.17 months (range, < one month - 92 months). Those who had ocoregional therapy had the longest median survival (30.33 months), followed by systemic chemotherapy (26.67
months) then surgery (13.17 months).
CONCLUSION: Among HCC patients In our institution, chronic hepatitis B was found to be the primary risk factor for its development. Median survival was 13.17 months with longest median survival among those who received locoregional treatment. Child-Turcotte-Pugh C (CTP C), BCLC stages C and D were independent predictors of mortality.